Maple Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
CS
O
Maple Capital Management's XBI Position: Q1 2016 in Review
Maple Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2016, closing a stake of 19,460 shares — an estimated $1.37M sold.
Maple Capital Management first reported a position in XBI in Q3 2015 and held it in 2 quarters. The position peaked at $1.37M in Q4 2015. 195 funds tracked by Wall St. Rank hold XBI as of Q1 2016.
- Maple Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2016 after selling out during the quarter.
- Maple Capital Management sold 19,460 State Street SPDR S&P Biotech ETF shares in Q1 2016, an estimated $1.37M.
- Maple Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 2 quarters.
- Maple Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.37M in Q4 2015.
- 195 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2016.
Based on Maple Capital Management's 13F filing for Q1 2016, filed 13 May 2016.